Survivorship — Life During and After Cancer

In contemporary oncology, survivorship conceptualises the holistic experience of living with, through, and beyond cancer. While historical definitions often restricted the concept to patients who achieved disease-free status following curative therapy, international oncology consensus recognizes survivorship as starting at initial diagnosis and continuing throughout the life course.

Clinically, survivorship focuses on the unique healthcare needs that emerge after acute treatment ends. This includes managing persistent late adverse effects, addressing chronic pain, fatigue, and neuropathy, screening for secondary primary neoplasms, and offering psychological support for anxiety and depression. Survivorship care also extends to practical considerations, such as assisting patients with employment reintegration, insurance barriers, and maintaining familial and social relationships.

Survivorship matters because modern cancer therapies allow many more individuals to live long lives after diagnosis, making long-term quality of life an essential clinical priority. Patients often experience a 'cliff effect,' feeling vulnerable or abandoned when frequent medical appointments stop. Recognising survivorship ensures that late effects—such as cardiovascular disease, secondary cancers, neuropathy, and persistent emotional trauma—are proactively managed. It empowers patients with self-management strategies, lifestyle guidance, and access to rehabilitation services, ensuring that extended life is accompanied by physical vitality and emotional resilience.

Survivorship does not rely on a single diagnostic test; instead, it incorporates comprehensive health screening, patient-reported outcome measures (PROMs), and risk-stratified testing. Clinicians assess organ function using echocardiograms for cardiotoxicity, bone mineral density scans (DEXA) for osteoporosis caused by hormone therapies, and routine blood panels evaluating kidney and liver health. Standardised questionnaires screen for persistent cancer-related fatigue, cognitive dysfunction, neuropathy, anxiety, and depression during follow-up visits.

Survivorship is relevant across all malignancies, but features prominently in cancers with high five-year survival rates, including breast, prostate, testicular, and thyroid cancers, as well as Hodgkin lymphoma and childhood cancers. Patients living with chronic or metastatic cancers, such as advanced melanoma or metastatic breast cancer managed with targeted therapies, also experience extended survivorship phases, balancing long-term treatment side effects with daily life over many years.

Survivorship considerations increasingly shape initial cancer treatment choices. Oncologists frequently choose treatments that minimise long-term toxicity—such as using breast-conserving surgery or omitting anthracyclines—when outcomes remain equivalent. In the post-treatment phase, survivorship care guides supportive therapies, including physical therapy, exercise prescriptions, psychosexual counselling, and dietary interventions. It also coordinates transition back to primary care, ensuring general practitioners manage chronic comorbidities alongside oncology teams without compromising ongoing cancer surveillance.